Evid Science’s founder and CEO, Matt Michelson, spoke to Thrive Global about the future of healthcare and how AI is transforming the industry. Evid Science is helping to “free” all of the scientific data locked away in publications and journals. … Read More
SPRIM Ventures in partnership with Tikehau Capital is hosting a Ventures Day event in New York on April 24. … Read More
Fibronostics presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore. The event was attended by current and potential investors in the TKS 1 fund, including venture capitalists, strategic investors, family offices and leaders from the healthcare industry. … Read More
Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States. … Read More
Going strong in its second time, together with Tikehau Capital, SPRIM held TKS 1 Investor Day on Friday, January 25, 2019, at the Four Seasons Hotel in Singapore. We invited all teams, shareholders, and partners of the ventures for this event … … Read More
RegAsk uses artificial intelligence to answer regulatory questions, including inquiries about path-to-market, path-to-claim, product registration and regulatory strategy. … Read More
ObvioHealth, meanwhile, has developed an app that enables studies to be run using mobile devices. Data from smart devices such as a Bluetooth blood pressure monitor can integrate with the app, according to the company, which earlier this year raised … Read More
MILO & CLAIMIT View a short, imagined study where ObvioHealth’s Milo demonstrates how digital technology improves patient experience, compliance and data capture using ClaimIt. Follow our fictional subject, Milo, as he uses his mobile phone to participate in a clinical … Read More
The blood brain barrier (BBB) is a system of blood vessels that protects the brain from toxins and chemical fluctuations. While it is necessary to help keep the brain healthy, it also poses a problem in delivering medications that could … Read More
NEW YORK (Reuters Health) – A commercially available formula of Lactobacillus acidophilus and L. casei prevents Clostridium difficile infection and diarrhea during antibiotic treatment, according to a single-center study from China. Although meta-analyses indicate that probiotics decrease antibiotic-associated diarrhea, most … Read More
Lack of diversity within the clinical trial industry poses a grave problem. We cannot assume medicines work similarly across ethnicities. While attracting and retaining minority groups to participate in clinical trials has become a primary focus in the industry, many … Read More
LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science companies. “Our technology is … Read More
BUSINESSWIRE, 12 February 2018 NEW YORK–(BUSINESS WIRE)–A double-blind, randomized, cross-over study, published in the UK-based, peer-reviewed Nutrition Journal, reported that consumption of milk containing only A2 beta casein protein type (sold in the US as a2 Milk®) reduced acute gastrointestinal … Read More
Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based drug discovery company. Travecta plans to use the Duke-NUS technology to develop new … Read More
HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS). Travecta is based on … Read More
LIFE science startups hoping for a big break can now look to a new Singapore-based cash cow for funding.European asset manager Tikehau Capital and Sprim Ventures, the venture arm of global healthcare consultancy Sprim, have teamed up to launch a … Read More
PHILADELPHIA — Sept. 13 2018 – Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, announces it has appointed Douglas … Read More
Conducting business globally is an essential piece to many business strategies. However, we often see clients fail to realize the depth of planning required for geo-expansion of a product or brand. From getting the product registered and making on-pack claims, … Read More
Marketing to doctors (a.k.a medical marketing, health marketing, professional marketing) is a core marcomm tactic that helps brands stand out against the blaring noise on neighboring store shelves. Naturally, as companies have abused this system to scrounge up market share, we’ve … Read More
PHILADELPHIA–(BUSINESS WIRE)–Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain development. … Read More
A Patient (and consultant’s) Point-of-View on Patient Services Imagine, as a patient, you leave the doctor’s office having been diagnosed with a chronic disease. The treatment calls for heavy doses of medication and changed lifestyle habits. You pestered the doctor … Read More
Medicines don’t work if patients don’t take them. It’s one of the biggest culprits in healthcare’s nearly $300 billion problem. Estimates show poor adherence causes approximately 125,000 deaths and at least 10 percent of hospitalizations annually. Patient Engagement Programs Pharma companies are actively … Read More
ORLANDO, Fla.–(BUSINESS WIRE)–ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies—ClaimIt. ClaimIt removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, lowering drop-out rates and … Read More
Failure rates of new product launches vary by industry, but most stats hover at or just below the 50 percent mark. There are dozens of reasons for these failures, and our engagement leaders see them daily. The categories where our clients … Read More
ObvioHealth, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding. The company is focused on making clinical trials faster and more cost-effective by digitizing the entire process … Read More
TKS 1 is an early-stage venture fund investing in digital healthcare companies set up by SPRIM Ventures and Tikehau Capital.
This unique partnership combines SPRIM’s domain expertise and experience in the healthcare industry with Tikehau’s financial engineering capability and strength.
As the healthcare and life sciences industry is on the verge of radical transformation with the application of new technology and the use of artificial intelligence, TKS 1 seeks to capture exciting opportunities in this evolving space as it focuses on two core themes: digitalization and artificial intelligence.
SPRIM Ventures partners with Tikehau Capital TKS 1 to provide an early-stage venture fund investing in digital healthcare companies.